Umckalor (15 film-coated tablets)

The instruction for medical use of Umkalor Umckalor Torgovoye medicine a name Umkalor Umckalor Mezhdunarodnoye the unlicensed name Is not present the Dosage form of the Tablet, film coated Structure One tablet contains active agent: the roots Pelargonium sidoides of extract liquid dried up (1:8-10) (EPs 7630) – 20.00 mg (extractant ethanol of 11%), excipients: maltodextrin, cellulose microcrystalline, lactoses monohydrate, sodium of a kroskarmelloz, silicon the dioxide besieged magnesium stearate, a cover: gipromeloza of 5 mPas, macrogoal 1500, ferrous oxide yellow (E 172), ferrous oxide red (E 172), titan dioxide (E 171), talc, protivospenivayushchy emulsion dry matter **. consists of: a simetikona – 92.02%, methyl celluloses – 7.67% and sorbic acid – 0.31% the Description of the Tablet of round shape, film coated henna-red color. Pharmacotherapeutic group Drugs for elimination of symptoms of cold and cough. The ATX R05 code the Pharmacological Pharmacokinetics properties Umkalor represents the complex mix of a set of components considered in general as active agent. The separate substances given about pharmacokinetic properties are not available. The pharmacodynamics Umkalor contains extract from roots of the southern African plant Pelargonium sidoides In drug. Researches on animals showed that at oral use of extract on mice the reduction of symptoms of a disease was observed (not specific symptoms of a disease which occur in communication by an infection) and antioxidant properties were shown. During the researches in vitro the following effects of drug Umkalor were confirmed: stimulation of nonspecific protective mechanisms: - stimulation of frequency of fluctuations of fibers of a ciliate epithelium - modulation of synthesis of interferon and anti-inflammatory cytokines - stimulation of activity of NK cells - stimulation of phagocytosis, an expression of adhesive molecules, a chemotaxis, antimicrobic activity: - moderate direct antibacterial and anti-virus activity - strengthening/inhibition of adhesion of streptococci of group A to the dead / zhi-to vy epithelial cells - inhibition of activity of ß-laktamazy cytoprotective properties: - inhibition of activity of human leukocytic elastase - antioxidant properties. Indications Acute and persistent infections, especially respiratory infections and areas of an ear, throat and nose, for example, bronchitis, sinusitis, tonsillar tonsillitis, nasopharyngitis. The route of administration and doses to Adults and children are more senior than 12 years appoint on 1 tablet 3 times a day (in the morning, in the afternoon and in the evening). To children aged from 6 do12 years - on 1 tablet 2 times a day (in the morning and in the evening). Umkalor it is recommended to accept, without chewing, with small amount of liquid. Treatment duration should not exceed Duration of treatment 3 weeks. After weakening of symptoms it is recommended to continue administration of drug within several days for prevention of a recurrence of a disease. Side effects Infrequently (≥1/1,000 - & lt, 1/100) - gastrointestinal disorders Seldom (≥1/10,000 - & lt, 1/1,000) - a slight odontorrhagia or from a nose - reaction of hypersensitivity Are available separate messages about emergence of symptoms of an abnormal liver function after administration of drug Umkalor, is not established to relationship of cause and effect between these effects and use of drug, the frequency of emergence is unknown. The contraindication - hypersensitivity to active agent or to other components of drug - a serious illness of a liver - children's age up to 6 years - pregnancy, the lactation period Medicinal interactions So far of messages about drug interaction Umkalor with other medicines is not available. Special instructions If your state does not improve within one week if within several days you keep high temperature, in case of symptoms of an abnormal liver function and also if you have a short wind or a bloody phlegm, immediately see a doctor. It is not recommended to use drug to patients with rare hereditary diseases of intolerance of a galactose, lactose insufficiency or glyukozo-galaktozny malabsorption. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms Data on influence of drug on ability to run motor transport or work with other mechanisms are absent. The overdose Is not present data concerning overdose cases. The form of release and packing On 15 tablets, film coated, place in planimetric strip packaging from PVH/PVDH – a film and aluminum foil. On 1 and 2 planimetric strip packagings together with the instruction for medical use in the state and Russian languages put in a pack from cardboard. To Store storage conditions at a temperature not above 30 °C. To store out of children's reach! Not to use a period of storage of 5 years after an expiration date. Prescription status Without prescription the Producer Other Wilmar Schwab GmbH&Ko of KG, Wilmar Schwab Strasse, 4 76227, Karlsruhe Germany the Owner of the registration certificate Other Wilmar Schwab of GmbH&Ko of KG, Wilmar Schwab Strasse, 4 76227, Karlsruhe Germany the Organization - the packer of medicine Other Wilmar Schwab of GmbH&Ko of KG., Wilmar Schwab Strasse, 4 76227, Karlsruhe Germany the Exclusive representative of Alpen Pharm AG Burn, Switzerland the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods) of Alpen Pharm LLP of Almaty, mdt. Zhetysu-2, 80, quarter 54